Safety and efficacy of nivolumab for non-clear cell kidney cancer

Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC). However, most patients with non-clear cell RCC are excluded from clinical trials, and there is limited data on the effectiveness of nivolumab for the treatment of these patients. This phase IIIb/IV CheckMate 374 study was conducted to look at […]

read more

Safety and efficacy of immunotherapy rechallenge in patients with kidney cancer

There are a number of immune checkpoint inhibitor drugs available for the treatment of people with metastatic renal cell carcinoma (RCC), but the efficacy and safety of treating patients with two separate lines of immunotherapy (rechallenge) is unknown. This study looked at the safety and efficacy of rechallenge with an immune checkpoint inhibitor in patients […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more

Lenvatinib plus pembrolizumab shows promise in solid tumours

The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%). The combination was […]

read more

Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer

A recent literature review and network meta-analysis of phase 2/3 randomised, controlled clinical trials of approved first-line tyrosine kinase inhibitors (TKIs) involving more than 4,200 patients with metastatic renal cell carcinoma (RCC) has shown that cabozantinib, sunitinib, pazopanib, and tivozanib have similar efficacy, but tivozanib’s safety profile is superior to the profiles of the other […]

read more

Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less […]

read more

ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer

Results from the ENTRATA clinical trial to assess telaglenastat in combination with everolimus for patients with heavily pre-treated renal cell carcinoma were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Telaglenastat is a type of biological therapy called a glutaminase inhibitor that blocks the glutaminase enzyme, which is […]

read more

Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer

A recent study, published in Clinical Genitourinary Cancer reports a meta-analysis comparing the tolerability and efficacy of a 2 weeks on treatment/1 week off treatment sunitinib dosing schedule with the traditional 4/2 schedule in patients with metastatic renal cell carcinoma (mRCC). Data from 1173 patients were included in the meta-analysis. The study showed that progression-free […]

read more

ASCO 2019: Safety and efficacy of immune checkpoint inhibitors in patients with pre-existing autoimmune disorders

This study was presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago last month. The trial looked at 103 patients with a variety of different autoimmune disorders, such as psoriasis (22%), thyroiditis (20%), rheumatoid arthritis (13%), polymyalgia rheumatica (8%), inflammatory bowel disease (6%), multiple sclerosis (3%) and lupus (3%) who […]

read more

Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

Results from this phase III trial of atezolizumab plus bevacizumab versus sunitinib for patients with untreated renal cell carcinoma (IMmotion 151) were published in The Lancet last month. The study involved 915 patients, of which 40% were positive for PD-L1 biomarkers. In the PD-L1 positive group of patients, the combination of atezolizumab plus bevacizumab was […]

read more
Showing 1 to 10 of 16 results
  TOP